Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker, C Nilsson, S Heinrich, D Helle, S O'Sullivan, J Fosså, S Chodacki, A Wiechno, P Logue, John P Seke, M
Parker, C
Nilsson, S
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Seke, M
Citations
Altmetric:
Abstract
Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.
Authors
Parker, C
Nilsson, S
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Seke, M
Widmark, A
Johannessen, D
Hoskin, P
Bottomley, D
James, N
Solberg, A
Syndikus, I
Kliment, J
Wedel, S
Boehmer, S
Dall'Oglio, M
Franzén, L
Coleman, R
Vogelzang, N
O'Bryan-Tear, C
Staudacher, K
Garcia-Vargas, J
Shan, M
Bruland, Ø
Sartor, O
Nilsson, S
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Seke, M
Widmark, A
Johannessen, D
Hoskin, P
Bottomley, D
James, N
Solberg, A
Syndikus, I
Kliment, J
Wedel, S
Boehmer, S
Dall'Oglio, M
Franzén, L
Coleman, R
Vogelzang, N
O'Bryan-Tear, C
Staudacher, K
Garcia-Vargas, J
Shan, M
Bruland, Ø
Sartor, O
Description
Date
2013-07-18
Publisher
Collections
Keywords
Type
Article
Citation
Alpha emitter radium-223 and survival in metastatic prostate cancer. 2013, 369 (3):213-23 N Engl J Med